Display options
Cite
Szturz P, Wouters K, Kiyota N, et al. Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Front Oncol. 2019;9:86doi: 10.3389/fonc.2019.00086.
Szturz, P., Wouters, K., Kiyota, N., Tahara, M., Prabhash, K., Noronha, V., Adelstein, D., Van Gestel, D., & Vermorken, J. B. (2019). Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Frontiers in oncology, 986. https://doi.org/10.3389/fonc.2019.00086
Szturz, Petr, et al. "Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer." Frontiers in oncology vol. 9 (2019): 86. doi: https://doi.org/10.3389/fonc.2019.00086
Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, Adelstein D, Van Gestel D, Vermorken JB. Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Front Oncol. 2019 Feb 21;9:86. doi: 10.3389/fonc.2019.00086. eCollection 2019. PMID: 30847300; PMCID: PMC6394212.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2019 Feb 21;9:86. doi: 10.3389/fonc.2019.00086. eCollection 2019.

Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer.

Frontiers in oncology

Petr Szturz, Kristien Wouters, Naomi Kiyota, Makoto Tahara, Kumar Prabhash, Vanita Noronha, David Adelstein, Dirk Van Gestel, Jan B Vermorken

Affiliations

  1. Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  2. Scientific Coordination and Biostatistics, Antwerp University Hospital, Edegem, Belgium.
  3. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  4. Kobe University Hospital Cancer Center Kobe, Japan.
  5. Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  6. Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  7. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States.
  8. Department of Radiotherapy, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  9. Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.

PMID: 30847300 PMCID: PMC6394212 DOI: 10.3389/fonc.2019.00086

Abstract

In locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN), concurrent chemoradiotherapy is an integral part of multimodality management both in the adjuvant and in the definitive settings. Although de-intensification strategies have been propelled to the forefront of clinical research in human papillomavirus (HPV) positive oropharyngeal cancer, three cycles of 100 mg/m

Keywords: chemoradiotherapy; cisplatin; clinical trials; cumulative dose; fractionation; head and neck cancer; practice recommendations

References

  1. N Engl J Med. 1999 Apr 15;340(15):1144-53 - PubMed
  2. J Clin Oncol. 2003 Jan 1;21(1):92-8 - PubMed
  3. N Engl J Med. 2003 Nov 27;349(22):2091-8 - PubMed
  4. J Clin Oncol. 2004 Jan 1;22(1):69-76 - PubMed
  5. N Engl J Med. 2004 May 6;350(19):1937-44 - PubMed
  6. N Engl J Med. 2004 May 6;350(19):1945-52 - PubMed
  7. Med Oncol. 2004;21(2):95-107 - PubMed
  8. J Clin Oncol. 2004 Dec 1;22(23):4657-9 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):762-71 - PubMed
  10. J Natl Cancer Inst. 2005 Apr 6;97(7):536-9 - PubMed
  11. N Engl J Med. 2006 Feb 9;354(6):567-78 - PubMed
  12. Lancet. 2006 Sep 2;368(9538):843-54 - PubMed
  13. J Clin Oncol. 2008 Jul 20;26(21):3582-9 - PubMed
  14. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):243-6 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1081-8 - PubMed
  16. Ann Oncol. 2010 Nov;21(11):2272-7 - PubMed
  17. BMJ. 2010 Sep 28;341:c4690 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):719-25 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):270-5 - PubMed
  20. Asia Pac J Clin Oncol. 2011 Sep;7(3):287-92 - PubMed
  21. Lancet Oncol. 2012 Feb;13(2):145-53 - PubMed
  22. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205 - PubMed
  23. J Clin Oncol. 2013 Mar 1;31(7):845-52 - PubMed
  24. Radiat Oncol. 2012 Dec 18;7:215 - PubMed
  25. J Clin Oncol. 2013 Dec 20;31(36):4550-9 - PubMed
  26. Jpn J Clin Oncol. 2014 Aug;44(8):770-4 - PubMed
  27. Head Neck. 2016 Feb;38(2):202-7 - PubMed
  28. J Clin Oncol. 2014 Dec 1;32(34):3858-66 - PubMed
  29. Head Neck. 2016 Apr;38 Suppl 1:E2151-8 - PubMed
  30. J Clin Oncol. 2015 Dec 10;33(35):4202-9 - PubMed
  31. Rep Pract Oncol Radiother. 2015 Sep-Oct;20(5):328-39 - PubMed
  32. Oral Oncol. 2016 Feb;53:10-6 - PubMed
  33. Lancet Oncol. 2016 Apr;17(4):440-451 - PubMed
  34. JAMA Otolaryngol Head Neck Surg. 2016 Dec 1;142(12):1164-1170 - PubMed
  35. Eur J Cancer. 2016 Nov;67:174-182 - PubMed
  36. Oncologist. 2017 Sep;22(9):1056-1066 - PubMed
  37. Lancet Oncol. 2017 Sep;18(9):1221-1237 - PubMed
  38. J Clin Oncol. 2018 Apr 10;36(11):1064-1072 - PubMed
  39. Oral Oncol. 2018 Jan;76:52-60 - PubMed
  40. J Natl Cancer Inst. 2018 Sep 18;:null - PubMed
  41. Lancet. 2019 Jan 5;393(10166):51-60 - PubMed
  42. Lancet. 2019 Jan 5;393(10166):40-50 - PubMed
  43. Clin Pharmacol Ther. 1986 Feb;39(2):136-44 - PubMed
  44. Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069-74 - PubMed
  45. Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004 - PubMed

Publication Types